← All organizations
Highest phase reached
Phase 3
First clinical trial
May 1, 2009Last known activity
Jun 13, 2024
Timeline
2000s
- Jun 1, 2003
Aprea Therapeutics AB— Founded
2020s
- May 17, 2022
Atrin Pharmaceuticals— Acquired
Drugs by trial phase (12 distinct, 13 trials)
Phase 3 (2 own, 0 via acquisition)
Phase 2 (7 own, 1 via acquisition)
Indications
Studied for
- Carcinoma, Ovarian Epithelial
- Carcinoma, Transitional Cell
- Hematologic Neoplasms
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Leukemia, Myelomonocytic, Chronic
- Leukemia, Myelomonocytic, Juvenile
- Lymphoma
- Lymphoma, Mantle-Cell
- Lymphoma, Non-Hodgkin
- Melanoma
- Myelodysplastic Syndromes
- Myeloproliferative Disorders
- Neoplasms
- Ovarian Neoplasms
- Preleukemia
- Prostatic Neoplasms
- Syndrome
Subsidiaries (1 direct, 1 total across the full acquisition tree)
Recent trials (12)
- NCT06260514Lead sponsorPhase 1Jun 13, 2024
- NCT04638309Lead sponsorPhase 1Sep 20, 2021
- NCT04419389Lead sponsorPhase 1/Phase 2Sep 30, 2020
- NCT04383938Lead sponsorPhase 1/Phase 2Jul 31, 2020
- NCT04214860Lead sponsorPhase 1Dec 13, 2019
- NCT03931291Lead sponsorPhase 2May 30, 2019
- NCT03745716Lead sponsorPhase 3Jan 11, 2019
- NCT03588078CollaboratorPhase 1/Phase 2Sep 15, 2018
- NCT03391050Lead sponsorPhase 1/Phase 2Jan 18, 2018
- NCT03268382Lead sponsorPhase 2Jul 31, 2017
- NCT02098343Lead sponsorPhase 1/Phase 2Mar 1, 2014
- NCT00900614Lead sponsorPhase 1May 1, 2009
Details
- Founded
- Stockholm, SE Jun 1, 2003
- Last known activity
- Jun 13, 2024